Sophie Piperno-Neumann1,*, Pascale Mariani2, Vincent Servois3, Gaelle Pierron4, Livia LumbrosoRouic5, Alexandre Matet5,6, Manuel Rodrigues1, Nathalie Cassoux5,6
Oncologie, Vol.22, No.4, pp. 203-212, 2020, DOI:10.32604/oncologie.2020.014102
Abstract Uveal melanoma is a rare subtype of melanoma, intrinsically
different from cutaneous melanoma. Despite optimal therapeutic management
allowing local control of the primary ocular tumor, 20 to 50% of patients
develop metastases, mainly localized to the liver, with a poor prognosis and a
12-month median survival from the diagnosis of the metastatic disease. There is
a lack of effective treatments in the metastatic setting, and dedicated strategies
and trials for uveal melanoma patients are needed, based on identification of
new targets and specific preclinical findings.
Résumé:
Le mélanome de l’uvée est un cancer rare, en tous points différent du
mélanome… More >
Login
Register
